Sobotka Lindsay, Hinton Alice, Conteh Lanla
Department of Internal Medicine, the Ohio State University Wexner Medical Center, Columbus, OH 43210, United States.
Division of Biostatistics, College of Public Health, the Ohio State University, Columbus, OH 43210, United States.
World J Hepatol. 2017 Dec 28;9(36):1346-1351. doi: 10.4254/wjh.v9.i36.1346.
To evaluate disparities in the treatment of hepatocellular carcinoma (HCC) based on gender.
A retrospective database analysis using the Nationwide Inpatient Sample (NIS) was performed between 2010 and 2013. Adult patients with a primary diagnosis of hepatocellular carcinoma determined by International Classification of Disease 9 (ICD-9) codes were included. Univariate analysis and multivariate logistic regressions were performed to analyze differences in treatment, mortality, features of decompensation, and metastatic disease based on the patient's gender.
The analysis included 62582 patients with 45908 men and 16674 women. Women were less likely to present with decompensated liver disease (OR = 0.84, < 0.001) and had less risk of inpatient mortality when compared to men (OR = 0.75, < 0.001). Women were more likely to receive inpatient resection (OR = 1.31, < 0.001) or an ablation (OR = 1.22, = 0.028) than men. There was no significant difference between men and women in regard to liver transplantation and transcatheter arterial chemoembolization (TACE).
Gender impacts treatment for hepatocellular carcinoma. Women are more likely to undergo an ablation or resection then men. Gender disparities in transplantation have resolved.
评估基于性别的肝细胞癌（HCC）治疗差异。
利用全国住院患者样本（NIS）进行2010年至2013年的回顾性数据库分析。纳入根据国际疾病分类第9版（ICD - 9）编码确诊为原发性肝细胞癌的成年患者。进行单因素分析和多因素逻辑回归分析，以分析基于患者性别的治疗、死亡率、失代偿特征和转移性疾病的差异。
分析纳入62582例患者，其中男性45908例，女性16674例。与男性相比，女性出现失代偿性肝病的可能性较小（OR = 0.84，<0.001），住院死亡率风险较低（OR = 0.75，<0.001）。女性比男性更有可能接受住院切除（OR = 1.31，<0.001）或消融治疗（OR = 1.22，= 0.028）。在肝移植和经动脉化疗栓塞（TACE）方面，男性和女性之间没有显著差异。
性别影响肝细胞癌的治疗。女性比男性更有可能接受消融或切除治疗。移植方面的性别差异已经消除。
